Details for Patent: 10,842,800

Which drugs does patent 10,842,800 protect, and when does it expire?

Patent 10,842,800 protects KORLYM and is included in one NDA.

This patent has fifteen patent family members in ten countries.

Summary for Patent: 10,842,800

Title:	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Abstract:	Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions. Applicant has surprisingly found that GRAs may be administered to subjects receiving CYP3A inhibitors or steroidogenesis inhibitors such as ketoconazole without increasing risk adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole (a CYP3A inhibitor and a steroidogenesis inhibitor), providing safe concomitant administration of the GRA and ketoconazole. In embodiments, the GRA dose may be reduced.
Inventor(s):	Joseph K. Belanoff
Assignee:	Corcept Therapeutics Inc
Application Number:	US16/219,564
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,842,800
Patent Claim Types: see list of patent claims	Use;

error: insufficient information

Drugs Protected by US Patent 10,842,800

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,842,800					TREATING CUSHING'S SYNDROME

International Family Members for US Patent 10,842,800

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018229355
Canada	3052668
China	110352058